DNA vaccines for therapy of tuberculosis: where are we now?
DNA vaccines that were being investigated in mice for prophylactic use against tuberculosis were soon found also to be surprisingly effective as treatment against established infection. The immune system was stimulated to kill the bacteria, even including the persistent latent bacteria that are otherwise refractory to the immune system and antibacterial chemotherapeutic drugs alike. Subsequent results from a range of laboratories using diverse DNA vaccines in diverse murine models of infection have been very varied, ranging from enhanced pathology, through negligible effects, to major additive benefit from combined vaccine and chemotherapy. This review summarises the data and assesses future prospects.
Lowrie
Douglas B
DB
National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK. dlowrie@nimr.mrc.ac.uk
D000818:Animals; D003131:Combined Modality Therapy; D004269:DNA, Bacterial / Q000502:physiology; D004358:Drug Therapy; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000502:physiology; D014376:Tuberculosis / Q000188:drug therapy*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use*; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000627:therapeutic use*
D004269:DNA, Bacterial; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA